A comparison of IGF-I levels measured by two commercially available radioimmunoassays

1988 ◽  
Vol 119 (3) ◽  
pp. 333-338 ◽  
Author(s):  
A. Silbergeld ◽  
L. Jaber ◽  
P. Lilos ◽  
Z. Laron
Keyword(s):  
Growth Factor ◽  
Short Stature ◽  
Precocious Puberty ◽  
Insulin Like Growth Factor ◽  
Factor I ◽  
Igf I ◽  
Edta Plasma ◽  
The Mean ◽  
Growth Factor I ◽  
Parallel Fashion

Abstract. Insulin-like growth factor I levels were measured in a parallel fashion in 77 extracted sera using the INCSTAR RIA (radioimmunoassay) and in the EDTA plasma of the same subjects by the NICHOLS RIA. The subjects suffered from untreated hGH deficiency, short stature, delayed and precocious puberty and acromegaly. Significant differences (P < 0.05) were found between the mean IGF-I levels of all groups using both RIA systems. However, using the INCSTAR RIA, 85% of IGF-I values in untreated hGH deficiency were below normal, and a rise in IGF-I detected in the sera of all 5 patients who were treated with hGH. Using NICHOLS RIA, 55% of basal IGF-I values were below normal and a hGH-stimulated rise in IGF-I was found in only two of the treated patients. The INCSTAR RIA seems more precise and reproducible than the NICHOLS RIA and enables better discrimination of hGH-deficient patients from age-matched controls.

Plasma clearance and tissue distribution of labelled insulin-like growth factor-I (IGF-I), IGF-II and des(1–3)IGF-I in rats

1991 ◽  
Vol 128 (2) ◽  
pp. 197-204 ◽  
Author(s):  
F. J. Ballard ◽  
S. E. Knowles ◽  
P. E. Walton ◽  
K. Edson ◽  
P. C. Owens ◽  
...  
Keyword(s):  
Growth Factor ◽  
Binding Proteins ◽  
Rank Order ◽  
Insulin Like Growth Factor ◽  
Plasma Binding ◽  
Factor I ◽  
Igf I ◽  
The Mean ◽  
Growth Factor I ◽  
Sites Of Action

ABSTRACT Incubation of 125I-labelled insulin-like growth factor-I (IGF-I) with rat plasma at 4 °C led to the transfer of approximately half the radioactivity to 150 kDa and smaller complexes with IGF-binding proteins. The extent of association was greater with labelled IGF-II and essentially absent with the truncated IGF-I analogue, des(1–3)IGF-I. A greater degree of binding of IGF peptides with binding proteins occurred after i.v. injection of the tracers into rats, but most of the des(1–3)IGF-I radioactivity remained free. Measurement of the total plasma clearances showed the rapid removal of des(1–3)IGF-I compared with IGF-I and IGF-II; the mean clearances were 4·59, 1·20 and 1·34 ml/min per kg respectively. The mean steadystate volume of distribution was larger for des(1–3)IGF-I than for IGF-I and IGF-II (461, 167 and 181 ml/kg respectively), probably because of the differences in plasma protein binding. With all tracers, radioactivity appeared in the kidneys to a greater extent than in other organs. The amount of radioactivity found in the adrenals, brain, skin, stomach, duodenum, ileum plus jejunum and colon was in rank order, des(1–3)IGF-I > IGF-I > IGF-II. Since this ranking is the opposite of the abilities of the three IGF peptides to form complexes with plasma binding proteins, we propose that the plasma binding proteins inhibit the transfer of the growth factors to their tissue sites of action. Moreover, we suggest that IGF analogues that are cleared rapidly from blood may have greater biological potencies in vivo. Journal of Endocrinology (1991) 128, 197–204

Systemic metabolic effects of combined insulin-like growth factor–I and growth hormone therapy in patients who have sustained acute traumatic brain injury

2006 ◽  
Vol 105 (6) ◽  
pp. 843-852 ◽  
Author(s):  
Jimmi Hatton ◽  
Richard Kryscio ◽  
Melody Ryan ◽  
Linda Ott ◽  
Byron Young
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Treatment Group ◽  
Control Group ◽  
Insulin Like Growth Factor ◽  
Gh Therapy ◽  
Factor I ◽  
Igf I ◽  
The Mean ◽  
Growth Factor I

Object Hypermetabolism, hypercatabolism, refractory nitrogen wasting, hyperglycemia, and immunosuppression accompany traumatic brain injury (TBI). Pituitary dysfunction occurs, affecting growth hormone (GH) and plasma insulin-like growth factor–I (IGF-I) concentrations. The authors evaluated whether combination IGF-I/GH therapy improved metabolic and nutritional parameters after moderate to severe TBI. Methods The authors conducted a prospective, randomized, double-blind study comparing combination IGF-I/GH therapy and a placebo treatment. Ninety-seven patients with TBI were enrolled in the study within 72 hours of injury and were assigned to receive either combination IGF-I/GH therapy or placebo. All patients received concomitant nutritional support. Insulin-like growth factor–I was administered by continuous intravenous infusion (0.01 mg/kg/hr), and GH (0.05 mg/kg/day) was administered subcutaneously. Placebo control group patients received normal saline solution in place of both agents. Nutritional and metabolic monitoring continued throughout the 14-day treatment period. The two groups did not differ in energy expenditure, nutrient intake, or use of insulin treatment. The mean daily serum glucose concentration was higher in the treatment group (123 ± 24 mg/dl) than in the control group (104 ± 11 mg/dl) (p < 0.03). A positive nitrogen balance was achieved within the first 24 hours in the treatment group and remained positive in that group throughout the treatment period (p < 0.05). This pattern was not observed in the control group. Plasma IGF-I concentrations were above 350 ng/ml in the treatment group throughout the study period. Overall, the mean plasma IGF-I concentrations were 1003 ± 480.6 ng/ml in the treatment group and 192 ± 46.2 ng/ml in the control group (p < 0.01). Conclusions The combination of IGF-I and GH produced sustained improvement in metabolic and nutritional endpoints after moderate to severe acute TBI.

scholarly journals Infections and systemic inflammation are associated with lower plasma concentration of insulin-like growth factor I among Malawian children

2020 ◽  
Author(s):  
Kenneth Maleta ◽  
Yue-Mei Fan ◽  
Juho Luoma ◽  
Ulla Ashorn ◽  
Jaden Bendabenda ◽  
...  
Keyword(s):  
Growth Factor ◽  
Systemic Inflammation ◽  
Low Income ◽  
Insulin Like Growth Factor ◽  
Lower Plasma ◽  
Factor I ◽  
Malaria Parasitemia ◽  
Igf I ◽  
The Mean ◽  
Growth Factor I

ABSTRACT Background Insulin-like growth factor I (IGF-I) is the most important hormonal promoter of linear growth in infants and young children. Objectives The objectives of this study were to compare plasma IGF-I concentration in a low- compared with a high-income country and characterize biological pathways leading to reduced IGF-I concentration in children in a low-income setting. Methods We analyzed plasma IGF-I concentration from 716 Malawian and 80 Finnish children at 6–36 mo of age. In the Malawian children, we studied the association between IGF-I concentration and their environmental exposures; nutritional status; systemic and intestinal inflammation; malaria parasitemia and viral, bacterial, and parasitic enteric infections; as well as growth at 18 mo of age. We then conducted a pathway analysis to identify direct and indirect associations between these predictors and IGF-I concentration. Results The mean IGF-I concentrations were similar in Malawi and Finland among 6-mo-old infants. At age 18 mo, the mean ± SD concentration was almost double among the Finns compared with the Malawians [24.2 ± 11.3 compared with 12.5 ± 7.7 ng/mL, age- and sex-adjusted difference in mean (95% CI): 11.8 (9.9, 13.7) ng/mL; P &lt; 0.01]. Among 18-mo-old Malawians, plasma IGF-I concentration was inversely associated with systemic inflammation, malaria parasitemia, and intestinal Shigella, Campylobacter, and enterovirus infection and positively associated with the children's weight-for-length z score (WLZ), female sex, maternal height, mother's education, and dry season. Seasonally, mean plasma IGF-I concentration was highest in June and July and lowest in December and January, coinciding with changes in children's length gain and preceded by ∼2 mo by the changes in their WLZ. Conclusions The mean plasma IGF-I concentrations are similar in Malawi and Finland among 6-mo-old infants. Thereafter, mean concentrations rise markedly in Finland but not in Malawi. Systemic inflammation and clinically nonapparent infections are strongly associated with lower plasma IGF-I concentrations in Malawi through direct and indirect pathways.

Insulin-like growth factor I in the dog: a study in different dog breeds and in dogs with growth hormone elevation

1984 ◽  
Vol 105 (3) ◽  
pp. 294-301 ◽  
Author(s):  
J. E. Eigenmann ◽  
D. F. Patterson ◽  
J. Zapf ◽  
E. R. Froesch
Keyword(s):  
Growth Hormone ◽  
Growth Factor ◽  
Gel Chromatography ◽  
Insulin Like Growth Factor ◽  
Significant Drop ◽  
Factor I ◽  
Igf I ◽  
The Mean ◽  
Growth Factor I ◽  
The One

Abstract. A radioimmunoassay (RIA) devised for the measurement of human insulin-like growth factor I (IGF I) was employed for the measurement of canine IGF I. Canine IGF I was extracted from plasma specimens by gel chromatography. Columns were eluted with 1 m acetic acid and the fractions representing the 55 to 85% bed volume were pooled, lyophilized and reconstituted with assay buffer. Serial dilutions of canine IGF I from both normal and acromegalic dogs when added to the RIA system gave a similar displacement pattern of human [125I]IGF I as the one obtained by the addition of unlabelled human IGF I. The dose-response curve obtained by canine IGF I paralleled the one obtained by human IGF I. Logit-log transformation and least squares fitting resulted in straight line fitting of the standard curve between 0.039 and 5 ng IGF I added per tube. The within-assay coefficient of variation (CV) was 16.7% and the between-assay CV was 21.8%. Plasma IGF I concentrations in normal dogs appeared to be a function of body size. The concentrations were 36 ± 27 ng/ml in Cocker Spaniels, 87 ± 33 ng/ml in Beagles, 117 ± 34 ng/ml in Keeshonds, and 280 ± 23 ng/ml in German Shepherds (mean ± sem). The mean IGF I level in a group of dogs with growth hormone (GH) elevation was 700 ± 90 ng/ml. Though this group of dogs comprised both small and large dogs, the mean IGF I level significantly differed from the one found in German Shepherds, the largest breed studied (P < 0.01). IGF I levels in dogs with GH elevation were similarly elevated in both dogs exhibiting acromegaly and dogs exhibiting GH-diabetes, but no signs of acromegaly. In dogs with GH elevation, drop in GH levels was associated with a significant drop in IGF I levels.

Insulin-like growth factor I levels in proportionate dogs, chondrodystrophic dogs and in giant dogs

1988 ◽  
Vol 118 (1) ◽  
pp. 105-108 ◽  
Author(s):  
J. Eugen Eigenmann ◽  
Adel Amador ◽  
Donald F. Patterson
Keyword(s):  
Body Weight ◽  
Body Size ◽  
Growth Factor ◽  
Plasma Insulin ◽  
Plasma Concentrations ◽  
Insulin Like Growth Factor ◽  
Factor I ◽  
Igf I ◽  
The Mean ◽  
Growth Factor I

Abstract. Plasma insulin-like growth factor I concentrations from proportionate, chondrodystrophic and giant breeds were evaluated and compared with body size. IGF-I plasma concentrations were 91.2 ± 10.9 μg/l in Keeshounds (proportionate dog), 122.6 ± 25.4 μg/l in Bassethounds (chondrodystrophic dog) and 280 ± 22.8 μg/l in German Shepherds (proportionate dog). The highest IGF-I level (389.6 ± 24.2 μg/l) was found in the New Foundland, a giant breed (mean ± sem). The mean body weight was 11.8 ±0.4 kg in Keeshounds, 15.4 ± 1.4 kg in Bassethounds, 32 ± 1.5 kg in German Shepherds, and 45.6 ± 1.7 kg in New Foundlands (mean ± sem). Body weight and plasma IGF-I concentration were significantly correlated (y (IGF-I) = −7.43 + 8.7 × (body weight); P < 0.0001.

Sign in / Sign up

Export Citation Format

Share Document